IntrinsicIntrinsic
← All summaries

KEWAUNEE SCIENTIFIC CORP /DE/

KEQU
Financials & Chart →

Business Summary

Kewaunee Scientific Corporation operates in the laboratory, healthcare, and technical furniture and infrastructure products industry, designing, manufacturing, and installing steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks. The Company's acquisition of Nu Aire, Inc. in November 2024 added biological safety cabinets, CO2 incubators, ultralow freezers, animal handling equipment, pharmacy compounding isolators, and related parts and accessories, serving life sciences, healthcare, pharmacy, education, food and beverage, and industrial sectors. The Company considers the markets in which it competes to be highly competitive, with a significant amount of business involving competitive public bidding.

The Company's primary competitors are not named in the filing, but management states that the principal deciding factors in the highly competitive industry are price, product performance, and customer service, with a significant portion of business based upon competitive public bidding. The Company's competitive positioning is supported by its robust capabilities combined with Nu Aire's recognized market leadership, well-developed channel strategy, and established distribution partners in regions where the Company did not previously have a presence, accelerating its vision of becoming the market leader in the design and manufacturing of laboratory furniture and technical products.

The Company generates revenue through the design, manufacture, and installation of laboratory, healthcare, and technical furniture and infrastructure products, sold primarily through purchase orders and contracts submitted by customers directly or through dealers, subsidiaries in Singapore and India, and a national distributor. Products are sold principally to pharmaceutical, biotechnology, industrial, chemical and commercial research laboratories, educational institutions, healthcare institutions, governmental entities, and manufacturing facilities. The Company's international subsidiaries provide products and services including facility design, detailed engineering construction, and project management from the planning stage through testing and commissioning of laboratories.

The Company operates in two segments: Lab Products Group (LPG) and International. The LPG segment consists of operations based out of Statesville, North Carolina and the Nu Aire subsidiary based out of Plymouth, Minnesota, and generated sales of $214.9 million in fiscal year 2026, an increase of 19.8% compared to fiscal year 2025 sales of $179.4 million , predominantly related to the acquisition of Nu Aire. The International segment consists of foreign subsidiaries and generated sales of $67.1 million in fiscal year 2026, an increase of 9.9% from fiscal year 2025 sales of $61.1 million , primarily due to the delivery of projects in India that had experienced customer site delays in the prior year.

In November 2024, the Company completed the acquisition of Nu Aire, purchasing all outstanding capital stock for $55.0 million , subject to certain customary adjustments. $23.0 million of the purchase price payable at closing was funded pursuant to subordinated seller notes, and the remaining cash portion was funded in part through a $20.0 million committed senior secured revolving line of credit facility and a $15.0 million term loan provided by PNC Bank. The Company's order backlog at April 30, 2026 was $165.9 million , compared to $214.6 million at April 30, 2025, with LPG backlog of $118.8 million and International backlog of $47.1 million . The Company had no advances outstanding under its $20.0 million Revolving Credit Facility at April 30, 2026.

Net sales for fiscal year 2026 were $282.0 million , an increase compared to fiscal year 2025 sales of $240.5 million . Gross profit represented 28.5% of sales in fiscal year 2026 and 28.6% in fiscal year 2025. Operating expenses were $63.7 million and $51.1 million in fiscal years 2026 and 2025, respectively, representing 22.6% and 21.2% of sales. Net earnings attributable to Kewaunee Scientific Corporation were $9,618,000 , or $3.22 per diluted share, compared to $11,405,000 , or $3.83 per diluted share, for fiscal years ended April 30, 2026 and April 30, 2025, respectively. Net cash provided by operating activities was $18,633,000 in fiscal year 2026, compared to $14,783,000 in fiscal year 2025.

Business Outlook

Management states that the Company's ability to predict future demand for its products continues to be limited given its role as subcontractor or supplier to dealers for subcontractors, and demand is dependent upon the number of laboratory and healthcare construction projects planned and/or current progress in projects already under construction. The Company's earnings are also impacted by fluctuations in prevailing pricing for projects in the laboratory construction marketplace and costs of raw materials, including steel, wood, and epoxy resin.The Company's growth strategy includes expanding its worldwide customer base and international operations, with 28% of revenues derived from sales outside the United States in fiscal year 2026. The acquisition of Nu Aire is a key growth vector, as Nu Aire has established distribution partners in regions where the Company did not previously have a presence, accelerating the Company's vision of becoming the market leader in the design and manufacturing of laboratory furniture and technical products. The Company also continues to invest in the Corporate platform required to scale as a public company and accelerate its organic and inorganic growth strategy.

The Company made significant progress in its integration of Nu Aire, positioning the business for improved performance as life sciences market conditions recover, while also strengthening Kewaunee's balance sheet through the servicing and repayment of acquisition-related debt. The Company remains focused on disciplined capital allocation, operational execution, and serving customers with excellence entering fiscal year 2027.

Gross profit margin remained relatively consistent with the prior year at 28.5% in fiscal year 2026 versus 28.6% in fiscal year 2025, reflecting offsetting changes in margin performance across LPG and International operations. Operating expenses increased to 22.6% of sales in fiscal year 2026 from 21.2% in fiscal year 2025, largely attributable to the acquisition of Nu Aire, with increases in SG&A wages of $1,034,000 , increases to bad debt expenses of $275,000 , and increases to corporate governance costs of $229,000 , partially offset by decreases in consulting and professional fees of $522,000 .

Capital expenditures in fiscal year 2026 were $3,937,000 , funded primarily by operations and from financing activities. Fiscal year 2027 capital expenditures are anticipated to be approximately $6.0 million , expected to be funded primarily by operating activities, supplemented as needed by borrowings under the revolving credit facility. The Company believes that its sources of funds will be sufficient to support ongoing business requirements, including capital expenditures, through fiscal year 2027.

The Company spent $898,000 on research and experimentation expenditures during fiscal year 2026, compared to $919,000 in fiscal year 2025. No dividends were declared or paid on the Company's common stock during the last two fiscal years. The Company's share repurchase program, authorized by the Board of Directors, does not have an expiration date but does not obligate the Company to acquire any particular amount of Common Stock and may be terminated at any time.

The Company faces structural headwinds including the highly competitive nature of the industry with a significant amount of business involving competitive public bidding, and the burden of possible increases in labor and material costs between quotation of an order and delivery of product since prices are normally quoted on a firm basis. The Company's principal markets in the laboratory and healthcare building construction industry are subject to significant volatility due to various factors outside the Company's control, and declines in construction activity or demand for products could materially and adversely affect business and financial condition.

Geographic and regulatory constraints include risks inherent in international sales, as 28% of revenues were derived from sales outside the United States in fiscal year 2026, and 22% of net sales were derived in currencies other than U.S. dollars. The Company is subject to laws and regulations of numerous domestic and foreign jurisdictions, including economic sanctions laws, export laws, anti-corruption laws, and customs laws. Changes in U.S. trade policy, including the imposition of tariffs, could require the Company to increase prices to customers which may reduce demand, or result in lowering margins on products sold if unable to increase prices.

Risk Factors

The Company faces material risks including customer concentration, as sales to two domestic dealers and the national stocking distributor represented approximately 34% of sales in fiscal year 2026, and loss of all or part of sales to a large channel partner would have a material effect on revenues and profits. The Company is exposed to raw material cost risk, bearing the burden of possible increases in labor and material costs between quotation and delivery since prices are quoted on a firm basis, with principal raw materials including steel, wood, and epoxy resin. International operations expose the Company to risks inherent in foreign sales, with 28% of revenues derived outside the United States and 22% of net sales denominated in currencies other than U.S. dollars. The Company's goodwill and intangible assets, totaling $12,487,000 in goodwill and $16,294,000 in intangible assets at April 30, 2026, could become impaired if acquired businesses do not generate expected revenues or profits, which could have a material impact on operating results. Changes in U.S. trade policy, including tariffs already imposed or that may be imposed in the future, could require price increases reducing demand or result in lower margins if unable to increase prices.

Management Priorities

Management's message emphasizes that fiscal year 2026 results highlight meaningful progress on strategic priorities, particularly in light of the challenging operating environment. Key themes include continued investment in the Corporate platform required to scale as a public company and accelerate organic and inorganic growth strategy, significant progress in the integration of Nu Aire positioning the business for improved performance as life sciences market conditions recover, and strengthening the balance sheet through servicing and repayment of acquisition-related debt. Entering fiscal year 2027, management states the Company remains focused on disciplined capital allocation, operational execution, and serving customers with excellence.

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 7, MD&A — Results of Operations
  2. [2] Item 7, MD&A — Results of Operations
  3. [3] Item 7, MD&A — Results of Operations
  4. [4] Item 7, MD&A — Results of Operations
  5. [5] Item 7, MD&A — Results of Operations
  6. [6] Item 7, MD&A — Results of Operations
  7. [7] Item 7, MD&A — Introduction
  8. [8] Item 7, MD&A — Introduction
  9. [9] Item 7, MD&A — Introduction
  10. [10] Item 7, MD&A — Introduction
  11. [11] Item 1, Business
  12. [12] Item 1, Business
  13. [13] Item 7, MD&A — Results of Operations
  14. [14] Item 7, MD&A — Results of Operations
  15. [15] Item 7, MD&A — Liquidity and Capital Resources
  16. [16] Item 7, MD&A — Results of Operations
  17. [17] Item 7, MD&A — Results of Operations
  18. [18] Item 7, MD&A — Results of Operations
  19. [19] Item 7, MD&A — Results of Operations
  20. [20] Item 7, MD&A — Results of Operations
  21. [21] Item 7, MD&A — Results of Operations
  22. [22] Item 7, MD&A — Results of Operations
  23. [23] Item 7, MD&A — Results of Operations
  24. [24] Item 8, Consolidated Statements of Operations
  25. [25] Item 8, Consolidated Statements of Operations
  26. [26] Item 8, Consolidated Statements of Operations
  27. [27] Item 8, Consolidated Statements of Operations
  28. [28] Item 7, MD&A — Liquidity and Capital Resources
  29. [29] Item 7, MD&A — Liquidity and Capital Resources
  30. [30] Item 1A, Risk Factors — Risks Related to Operations
  31. [31] Item 7, MD&A — Results of Operations
  32. [32] Item 7, MD&A — Results of Operations
  33. [33] Item 7, MD&A — Results of Operations
  34. [34] Item 7, MD&A — Results of Operations
  35. [35] Item 7, MD&A — Results of Operations
  36. [36] Item 7, MD&A — Results of Operations
  37. [37] Item 7, MD&A — Results of Operations
  38. [38] Item 7, MD&A — Results of Operations
  39. [39] Item 7, MD&A — Liquidity and Capital Resources
  40. [40] Item 7, MD&A — Liquidity and Capital Resources
  41. [41] Item 1, Business — Research and Experimentation Expenditures
  42. [42] Item 1, Business — Research and Experimentation Expenditures
  43. [43] Item 1A, Risk Factors — Risks Related to Operations
  44. [44] Item 7A, Quantitative and Qualitative Disclosures About Market Risk
  45. [45] Item 1A, Risk Factors — Risks Specific to our Company
  46. [46] Item 1A, Risk Factors — Risks Related to Operations
  47. [47] Item 7A, Quantitative and Qualitative Disclosures About Market Risk
  48. [48] Item 8, Consolidated Balance Sheets
  49. [49] Item 8, Consolidated Balance Sheets
  50. [50] Item 8, Consolidated Statements of Operations
  51. [51] Item 8, Consolidated Statements of Operations
  52. [52] Item 8, Consolidated Statements of Operations
  53. [53] Item 8, Consolidated Statements of Operations
  54. [54] Item 8, Consolidated Statements of Operations
  55. [55] Item 8, Consolidated Statements of Operations
  56. [56] Item 8, Consolidated Statements of Operations
  57. [57] Item 8, Consolidated Statements of Operations
  58. [58] Item 7, MD&A — Results of Operations
  59. [59] Item 7, MD&A — Results of Operations
  60. [60] Item 8, Consolidated Statements of Operations
  61. [61] Item 8, Consolidated Statements of Operations
  62. [62] Item 8, Consolidated Statements of Operations
  63. [63] Item 8, Consolidated Statements of Operations
  64. [64] Item 8, Consolidated Statements of Operations
  65. [65] Item 7, MD&A — Results of Operations
  66. [66] Item 8, Consolidated Statements of Operations
  67. [67] Item 7, MD&A — Results of Operations
  68. [68] Item 8, Consolidated Balance Sheets
  69. [69] Item 8, Consolidated Balance Sheets
  70. [70] Item 8, Consolidated Balance Sheets
  71. [71] Item 8, Consolidated Balance Sheets
  72. [72] Item 8, Consolidated Balance Sheets
  73. [73] Item 8, Consolidated Balance Sheets
  74. [74] Item 8, Consolidated Balance Sheets
  75. [75] Item 8, Consolidated Balance Sheets
  76. [76] Item 8, Consolidated Balance Sheets
  77. [77] Item 8, Consolidated Balance Sheets
  78. [78] Item 7, MD&A — Results of Operations
  79. [79] Item 7, MD&A — Results of Operations

Analysis on 6/26/2026